Obsidian Therapeutics

We are a clinical stage biotech company developing a novel, first-in-class, genetically engineered tumor infiltrating lymphocyte (“TIL”) cell therapy to deliver transformative outcomes for patients suffering from solid tumor malignancies and expand the reach of TIL therapy. We’re currently investigating OBX-115 and enrolling patients in an ongoing clinical trial in advanced or metastatic melanoma and non-small cell lung cancer (NSCLC). We engineer cytoTIL™ therapies using our proprietary cytoDRiVE® platform technology to express regulated therapeutic proteins to enhance anti-tumor activity.

Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team focused on delivering transformative therapies in areas of greatest clinical need.

We’re proud of our diverse talented team and committed to cultivating an environment where each person feels a strong sense of belonging and is supported to continuously learn and contribute their best work. Our Research, Clinical and G&A teams are based in the heart of Cambridge, MA, and our Technical Development, Manufacturing & Quality team is based in our CMC facility in Bedford, MA. We offer competitive salary and benefits, and potential for employee ownership through stock options.

1030 Massachusetts Ave
Cambridge, MA 02138
  • Featured Employer Badge
NEWS
FDA
FDA Weekly Review looks at the FDA’s actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date: the risk of unintended consequences.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
Obsidian Therapeutics and three other pharmaceutical companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.
Per BioSpace’s 2020 U.S. Life Sciences Salary Report and 2020 U.S. Life Sciences Diversity & Inclusion Report, men out-earn women by 19.3%, which climbs to 47.6% when looking specifically at health care. Also, only 14% of women felt that opportunities for promotion were fair compared to 23% of their male counterparts.
IN THE PRESS